In one study, a dual-target vaccine addressing both PRAME and prostate-specific membrane antigen (PSMA) triggered CD8+ T-cell expansion in 15 of 24 prostate cancer patients, with several showing sustained disease stability over a six-month period (this included one out of 10 patients with metastatic melanoma). This evidence concerns the gene FOLH1 and prostate cancer.